Pharmacodynamic analysis of contractile potentiation by cholinesterase inhibitors in rats.
Pharmacological profiles of four cholinesterase (ChE) inhibitors: edrophonium, pyridostigmine, neostigmine, and ambenonium after to administration to rats were analyzed. A pharmacodynamic model was developed by considering acetylcholinesterase (AChE) inhibition, direct antagonism to the nicotinic receptor, and desensitization of the nicotinic receptor. Pharmacokinetics of these drugs are dose-independent and have similar volumes of distribution at steady state (0.4-0.6 L/kg various doses). The t1/2 increases in the order of neostigmine, edrophonium, pyridostigmine, and ambenonium. Inhibitory constants of ChE inhibitors to bovine erythrocyte AChE determined in vitro were 2019, 276, 26, and 3.7 nM for edrophonium, pyridostigmine, neostigmine, and ambenonium, respectively. The effect of ChE inhibitor was monitored as the increase of developed tension of triceps muscle induced by sciatic nerve stimulation. The maximum value of contractile tension after i.v. administration decreased at high doses of each drug and the dose-response curves were biphasic. Time courses of plasma concentration and contractile muscle tension were modeled to estimate the association/dissociation rate constants to AChE and the nicotinic receptor, desensitization rate constant of receptor and the dissociation constant of acetylcholine (ACh) to nicotinic receptor/basal acetylcholine level ratio (Kd/ACh0). The estimated Kd/ACh0 values were not dependent on the drug. A significant correlation between inhibitory constants of ChE inhibitors to AChE estimated by in vivo pharmacodynamic analysis and those determined by an in vitro enzyme kinetic study was shown, while the relationship between dissociation constants to nicotinic receptor estimated by in vivo pharmacodynamic analysis and those measured by an in vitro binding study was not clear. Other process such as desensitisization induced by endogenous ACh diffusion rate of drugs into the synaptic cleft, action of presynaptic receptors, etc., might contribute to the dose-effect relationship of ChE inhibitors.
Yamamoto
K
K
Department of Pharmacy, University of Tokyo Hospital, Faculty of Medicine, Japan.
Sawada
Y
Y
Iga
T
T
D000549:Ambenonium Chloride / Q000493:pharmacokinetics / Q000494:pharmacology; D000818:Animals; D002417:Cattle; D002800:Cholinesterase Inhibitors / Q000493:pharmacokinetics* / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004491:Edrophonium / Q000493:pharmacokinetics / Q000494:pharmacology; D007275:Injections, Intravenous; D008297:Male; D008954:Models, Biological; D009119:Muscle Contraction / Q000187:drug effects*; D009157:Myasthenia Gravis / Q000378:metabolism*; D009388:Neostigmine / Q000493:pharmacokinetics / Q000494:pharmacology; D011729:Pyridostigmine Bromide / Q000493:pharmacokinetics / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D012044:Regression Analysis; D012584:Sciatic Nerve / Q000187:drug effects
D002800:Cholinesterase Inhibitors; D009388:Neostigmine; D000549:Ambenonium Chloride; D004491:Edrophonium; D011729:Pyridostigmine Bromide